Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Antitumor T cells can be inhibited by a TGFβ rich tumor microenvironment. The authors develop bifunctional proteins comprising CTLA-4 or PD-L1 immune checkpoint-targeted antibodies fused to a “TGFβ trap” and show that they counteract tumor immune tolerance and enhance the efficacy of these antibodie...

Full description

Bibliographic Details
Main Authors: Rajani Ravi, Kimberly A. Noonan, Vui Pham, Rishi Bedi, Alex Zhavoronkov, Ivan V. Ozerov, Eugene Makarev, Artem V. Artemov, Piotr T. Wysocki, Ranee Mehra, Sridhar Nimmagadda, Luigi Marchionni, David Sidransky, Ivan M. Borrello, Evgeny Izumchenko, Atul Bedi
Format: Article
Language:English
Published: Nature Publishing Group 2018-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-02696-6

Internet

https://doi.org/10.1038/s41467-017-02696-6

Similar Items